Article
Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.
Cancer discovery - 3 Nov 2025
Baldacci Simon, Brea Elliott J, Facchinetti Francesco, Li Zhaorong, Ngo Kenneth, Malhotra Soumya, Booker Matthew A, Tolstorukov Michael Yevgeniy, Chakravarti Sachiv, Hinchey Conor, Mahadevan Navin R, Lococo Filippo, D'Agnelli Simona, Gnetti Letizia, Campanini Nicoletta, Leonetti Alessandro, Feng William W, Tsai Jeanelle A, Hartley Antja-Voy, Locquet Marie-Anaïs, Fournel Ludovic, Alifano Marco, Mansuet-Lupo Audrey, Saldanha Aisha, Haller William, Zasadil Lauren M, Zielinska Magdalena, Bui Karen, Tuladhar Bishma, Lizotte Patrick Hall, Ivanova Elena V, Sequist Lecia V, Gokhale Prafulla C, Paweletz Cloud P, Smith Eric L, Jänne Pasi A, Barbie David A
Abstract excerpt
EGFR tyrosine kinase inhibitors have dramatically improved outcomes for patients with EGFR-mutated non-small cell lung cancer (NSCLC), but relapse frequently occurs because of drug-tolerant persister (DTP) cells that can evolve and develop diverse mechanisms of drug resistance. In samples from patients with EGFR-mutated NSCLC treated with EGFR tyrosine kinase inhibitors in the neoadjuvant setting, we observed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.